Crystal packing modifies ligand binding affinity : The case of aldose reductase by Cousido-Siah, Alexandra et al.
Crystal packing modifies ligand binding affinity: The case of 
aldose reductase
Alexandra Cousido-Siah1, Tatiana Petrova2, Isabelle Hazemann1, André Mitschler1, 
Francesc X. Ruiz1, Eduardo Howard3, Stephan Ginell4, Cédric Atmanene5,6, Alain Van 
Dorsselaer5,6, Sarah Sanglier-Cianférani5,6, Andrzej Joachimiak4,*, and Alberto Podjarny1,*
1Department of Integrative Biology, IGBMC, CNRS, INSERM, Université de Strasbourg, Illkirch, 
France
2Institute of Mathematical Problems of Biology, Russian Academy of Sciences, Pushchino 
142290, Russia
3IFLYSIB, UNLP-CONICET, Calle 59, 789, B1900BTE, La Plata, Argentina
4Structural Biology Center, Biosciences Division, Argonne National Laboratory, Argonne, Illinois 
60439
5Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO), Université de Strasbourg, 
IPHC, 25 rue Becquerel 67087 Strasbourg, France
6CNRS, UMR7178, 67037 Strasbourg, France
Abstract
The relationship between the structures of protein–ligand complexes existing in the crystal and in 
solution, essential in the case of fragment-based screening by X-ray crystallography (FBS-X), has 
been often an object of controversy. To address this question, simultaneous co-crystallization and 
soaking of two inhibitors with different ratios, Fidarestat (FID; Kd = 6.5 nM) and IDD594 (594; Kd 
= 61 nM), which bind to h-aldose reductase (AR), have been performed. The subatomic resolution 
of the crystal structures allows the differentiation of both inhibitors, even when the structures are 
almost superposed. We have determined the occupation ratio in solution by mass spectrometry 
(MS) Occ(FID)/Occ(594) = 2.7 and by X-ray crystallography Occ(FID)/Occ(594) = 0.6. The 
occupancies in the crystal and in solution differ 4.6 times, implying that ligand binding potency is 
influenced by crystal contacts. A structural analysis shows that the Loop A (residues 122–130), 
which is exposed to the solvent, is flexible in solution, and is involved in packing contacts within 
the crystal. Furthermore, inhibitor 594 contacts the base of Loop A, stabilizing it, while inhibitor 
FID does not. This is shown by the difference in B-factors of the Loop A between the AR–594 and 
AR–FID complexes. A stable loop diminishes the entropic energy barrier to binding, favoring 594 
versus FID. Therefore, the effect of the crystal environment should be taken into consideration in 
the X-ray diffraction analysis of ligand binding to proteins. This conclusion highlights the need for 
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additional methodologies in the case of FBS-X to validate this powerful screening technique, 
which is widely used.
Keywords
protein crystallography; mass spectrometry; ligand soaking; competitive binding; high resolution 
crystallography
INTRODUCTION
The problem of characterizing ligand binding is a fundamental one for drug design. X-ray 
crystallography is a widely used method to determine the interactions between a potential 
drug and its target.1 This technique has been used widely to establish structure–activity 
relations (SAR) in the design of ligands for a pharmaceutical target.2 The concept of 
fragment screening has become increasingly popular to establish binding sites for ligands.3
From the beginning of protein crystallography, the question of the relationship between the 
structure observed in the crystal and the structure in solution has been posed. This question 
is also relevant for ligand binding studies, which have been done extensively, mainly in 
pharmaceutical companies.4 In this case, it is important to know to what extent the 
crystalline state affects the binding of the ligand and in particular its affinity. For instance, it 
is known that ligands often increase the order of the target protein.5 This may have an effect 
on packing contacts. On the other hand, packing contacts could have an effect on ligand 
affinity. These questions are of great practical importance, since the possibility of ligand 
exchange in the crystal would greatly simplify binding experiments, for instance, the 
systematic screening of ligand–target complexes, as in the case of fragment-based screening 
by X-ray crystallography (FBS-X), a methodology used to determine hit compounds for a 
pharmaceutical target, which relies on the possibility of the competition between the ligands 
and their exchange in the crystal.
As has been noted several times in the past (for a recent example, see Ma et al.6), it is 
possible to bind multiple and diverse ligands to the same site of the protein in the crystal. 
The fact that different protein/ligand complexes have different unit cells and even different 
space groups might suggest that changing the ligand could change the crystal packing, for 
example, the cocrystallization experiment done with Saquinavir and Ritonavir versus HIV 
Protease.7
In order to compare binding occupancies in solution and in the crystal, we have designed a 
competition experiment in which two ligands targeting the same binding site of a protein are 
added simultaneously to the protein, and the experiment is repeated at different relative 
concentrations of the ligands. The binding occupancies are measured by mass spectrometry 
(MS) in solution and by X-ray crystallography by soaking the two inhibitors into a native 
crystal. The goal of the experiment is to accurately measure the ratios of ligand occupancies, 
and to determine whether there are changes when the complexes are in solution or in the 
crystalline state. We have also performed an experiment of simultaneous co-crystallization 
with two inhibitors.
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To be reliable, the experiment requires very accurate X-ray structures, temperature factors, 
and occupancies. We have, therefore, chosen to perform the experiments on human aldose 
reductase (AR), which diffracts up to 0.66 Å resolution.8 Also, to have significant 
differences, we have chosen two ligands, IDD-594 [594, Fig. 1(a)] and Fidarestat [FID, Fig. 
1(b)], which have very strong, but different binding modes.8,9 All known inhibitors of AR 
bind to the so-called “anion binding pocket,” which is built by Tyr48, Lys77, His110, 
Trp111, and the cofactor nicotinamide adenine dinucleotide phosphate (NADP)+. Most of 
the known inhibitors are addressing this area of the pocket by the carboxylic acid or by the 
hydantoin moiety. On the other hand, some of them also have another moiety, which binds 
to the so-called “specificity pocket,” formed by residues of the three external loops of AR 
adjacent to the anion binding pocket.10 In solution, FID binds AR more strongly (with the 
hydantoin moiety; Kd: 6.5 nM11) than 594 (with the carboxylic acid moiety; Kd: 61 nM12), 
as confirmed in the present study by competition experiments monitored by native MS and 
by IC50 measurements. To characterize the binding in solution, we have also measured the 
IC50 values (a measure of binding in the case of an enzyme).
This work shows that the binding occupancies are influenced by the crystal packing, and 
proposes an explanation. At the same time, we observe that it is possible to change very 
substantially the ligand binding site conformation while keeping the crystalline order, and 
indeed by keeping the same structure in most of the protein. This highlights the high 
adaptability of some proteins to different ligands. Thus, in spite of FBS-X suitability for 
obtaining high hit rates, alternative methodologies (like MS or surface plasmon resonance 
(SPR)) should be used in order to validate the results of this powerful high-throughput 
screening technique for the identification of drug leads.
MATERIALS AND METHODS
Native electrospray mass spectrometry
Prior to electrospray mass spectrometry (ESI-MS) experiments, purified AR was incubated 
with a two-fold molar excess of a freshly prepared NADP+ solution (Sigma Aldrich, St. 
Louis, MO). The holoenzyme was then dialyzed overnight at 4°C against 10 mM 
ammonium acetate buffer pH 6.8 using a 10 kDa molecular-weight cutoff Slide-A-Lyzer 
desalting unit (Thermo Scientific, Rockford, IL). Protein concentration was determined 
spectrophotometrically.
MS experiments were carried out on an electrospray time-of-flight mass spectrometer 
operating in the positive ion mode (MicrOTOF, Bruker Daltonics, Bremen, Germany). 
External calibration was done over the mass range m/z 500–5000 using the multiply charged 
ions produced by horse heart myoglobin (Sigma Aldrich, St. Louis, MO) diluted to 2 µM in 
1:1 acetonitrile/water mixture acidified with 1% formic acid. Samples were continuously 
infused into the ESI ion source at a flow rate of 3 µL/min. In-source collision dissociation, 
ion energy and collision energy voltages were, respectively, set to 30 V, 2 V, and 6 V in 
order to preserve the integrity of non-covalent complexes while achieving sufficient ion 
desolvation in the gas phase.
Cousido-Siah et al. Page 3
Proteins. Author manuscript; available in PMC 2015 December 07.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Protein integrity was first checked under denaturing conditions by diluting the protein to 2 
µM in 1:1 acetonitrile/water mixture acidified with 1% formic acid. The molecular weight 
measured under these conditions (36135.0 ± 0.6 Da) was found in good agreement with the 
mass of the apoenzyme calculated from its amino acid sequence (36134.6 Da—data not 
shown). Analysis of the holoenzyme in non-denaturing conditions leads to the detection of 
two major species: Species A corresponds to the apoprotein, while the Species B displays a 
mass difference of +744 Da and can therefore be assigned to the holoenzyme, that is, the 
protein complexed with one molecule of NADP+ (Fig. S1, Supporting Information). 
Competition experiments were performed by diluting the protein to 10 µM in 10 mM 
ammonium acetate buffer containing concentrations of FID (279.2 Da) and 594 (416.2 Da) 
ranging from 10 to 30 µM. Data processing was performed using Data Analysis 3.4 
(MicrOTOF, Bruker Daltonics, Bremen, Germany).
Crystallographic studies
We first tried co-crystallization of AR containing two molar excess of cofactor NADP+, 
following the published conditions8 with two molar excess of both inhibitors, 594 and FID, 
simultaneously. X-ray data were collected at the Advanced Photon Source (APS) (Argonne, 
USA) in 19-ID Structural Biology Center (SBC) beamline13 and processed with the program 
HKL2000.14 The crystal structure was solved with molecular replacement (AMoRe15) using 
the Protein Data Bank (PDB) 2I16 entry.16 The resulting maps showed an electron density 
only for 594.
We then soaked simultaneously for 6 days the inhibitors FID and 594 in drops containing 
AR/NADP+ crystals obtained at 24°C, with a protein molar concentration (Conc) estimated 
in the drop of 0.27 mM, in three ratios of inhibitor concentrations (FID vs 594), as follows:
1. FID > 594. Conc (FID) = 1.5 mM (5.5 × Conc(AR)); Conc (594) = 0.5 mM (1.8 × 
Conc(AR)).
2. FID = 594. Conc (FID) = 1.5 mM (5.5 × Conc(AR)); Conc (594) = 1.5 mM (5.5 × 
Conc(AR)).
3. FID < 594. Conc (FID) = 0.5 mM (1.8 × Conc(AR)); Conc (594) = 1.5 mM (5.5 × 
Conc(AR)).
These three soaking conditions correspond to equal concentrations and excess of one or the 
other of a factor 3. X-ray data were collected in 19-ID SBC beamline at APS up to 
subatomic resolution (between 0.85 and 0.9 Å) and processed with the program HKL2000.14 
The structures were solved by Molecular Replacement15 using the 2I16 PDB entry and 
refined with SHELXL.17 We will refer to them below as FID > 594, FID = 594, and FID < 
594.
Refinement—In this work, two different PDB entries were used for the already published 
single-inhibitor AR–594 complex. PDB entry 2I16,16 refined at 0.81 Å (approximately the 
same resolution range of the presented data) from crystals measured at helium temperature 
Additional Supporting Information may be found in the online version of this article
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(15 K) was used as the starting model for refinement of the models FID > 594, FID = 594, 
and FID < 594. PDB entry 1US0,8 re-refined in this work at 0.92 Å resolution (originally at 
0.66 Å), from crystals measured at liquid nitrogen temperatures (100 K) was used for B-
factor comparison, since the measurement temperature was the same as the one in this work. 
The refinement from the model 2I16 was carried out using the program SHELXL.17 First 
round of refinement for each model was performed with isotropic atomic displacement 
parameters (ADPs) values, then, ADPs were refined anisotropically. For the residues of the 
protein, distance, planarity and chiral volume restraints, and restraints for ADPs were 
applied. The anisotropic displacement components of the two bonded atoms along the line 
joining them were restrained to be equal (DELU restraints). The components of ADPs 
matrix were approximately equal for spatially closed atoms (SIMU restraints). An inspection 
of electron density maps and manual rebuilding of the model were done using the program 
Coot.18
While, at the first rounds of refinement, the model 2I16 with only 594 was used, negative 
peaks at Fobs − Fcalc difference map at positions of the atoms of the inhibitor indicated that 
occupancy of 594 was less than 1.00. At the same time, strong positive peaks in the 
difference map revealed also the presence of inhibitor FID in the active site. FID (PDB code 
1PWM9) was fitted into the map, and inhibitors 594 and FID together with the 
corresponding alternative positions of residues 299–305 and 309 were modeled as two 
conformations, A and B. A number of water molecules were incorporated to these alternate 
models based on the distances from the corresponding residues. Occupancy values of the 
alternates A and B were refined by the program SHELX in constraint that the sum of 
occupancy values of these alternates was equal to 1.0.
The occupancy value of the bromine (Br) atom of the inhibitor 594 was estimated separately 
in the refinement because of debromination caused by radiation-induced damage, with the 
restriction that the B value of Br had to be approximately equal to the B value of the 
covalently bound carbon atom.
Atomic coordinates and experimental structure factors for the models FID > 594, FID = 594, 
and FID < 594 were deposited into the PDB and are accessible under the codes 2PEV, 2PF8, 
and 2PFH, correspondingly. The final R-factor values and other refinement statistics are 
given in Table I. The occupancy values of alternates A, B, and Br atoms are given in Table 
II.
Comparison of the models FID > 594, FID = 594, and FID < 594 with the models containing 
only single-inhibitor AR–594 (2I16 and 1US0) and single-inhibitor FID (1PWM) revealed 
that all the conformations that were built in these two models also exists in the models FID 
> 594, FID = 594, and FID < 594. Similar observations can be done concerning water 
molecules. All the water molecules that were observed in the models 2I16 and 1US0 (594), 
and 1PWM (FID), were also observed in the models FID > 594, FID = 594, and FID < 594 
(but with different occupancy values).
After the main refinement was finished, a few additional rounds of occupancy refinement 
were performed in which occupancy values of the inhibitors and residues in the vicinity of 
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the active site were explored. Instead of only two alternates A and B, several independent 
alternates were considered. Occupancy values of the inhibitors, residues 299–305, and 
residue 309, were assigned by different variables and were refined independently from each 
other. Inhibitor 594 was considered as consisting of two parts, and occupancy values of each 
part were refined separately. The goal of these additional rounds of refinement was to 
determine to what extent occupancy values will deviate from the values that were obtained 
as a result of refinement of two unique alternates A and B. The final occupancy values are 
presented in Table II. For all three models, the difference between occupancy values 
obtained during main and additional rounds of refinement is very small, which can be 
considered as a confirmation that the approach to refine everything together as two 
alternates A and B was correct.
For the calculation of B-factors for the loop 122–130, the models for the single-inhibitor 
AR–594 complex (1US0), the single-inhibitor AR–FID complex (1PWM), the double-
inhibitor FID = 594, and the double-inhibitor FID < 594 were all refined anisotropically at 
0.92 Å resolution (the limit of the 1PWM data) using the program SHELX. The model and 
structure factor data for entries 1US0 (AR–594; 100 K data) and 1PWM (AR–FID; 100 K 
data) were downloaded from the PDB. The model FID > 594 was excluded from this 
analysis because, in the loop 122–130, some residues are in double conformation. The 
model 2I16 was not used in this comparison, because the data for this model were collected 
at 15 K.
IC50 studies
The IC50 activity assays were carried out according to a previously described method,19 
based on the quantification of NADPH consumption which takes place when the enzyme 
catalyses the conversion of glyceraldehyde into glycerol. The assays were performed at 
25°C in 100 mM sodium phosphate buffer pH 7.0, with AR protein amount to reach Vmax 
and 0.2 mM NADPH. The final reaction volume was of 500 µL per reaction. Both 
compounds assayed were dissolved in dimethyl sulfoxide, and the corresponding solution 
was added to the cell and incubated for 5 min at 25°C prior to addition of the substrate. The 
reaction was initiated by addition of 1 mM glyceraldehyde and the decrease in optical 
density at 340 nm was monitored for 3 min at 25°C in a UV–vis spectrophotometer 
(UV-1700 PharmaSpec, Shimadzu). The IC50 value was determined as the compound 
concentration that inhibits enzymatic activity by 50%. IC50 was calculated using the Grafit 
program (version 5.0; Erithacus Software) and values were given as the mean of three 
experiments ± the standard deviation.
RESULTS AND DISCUSSION
Solution studies
MS: Relative binding affinities of 594 and FID for AR were first studied in solution by 
native MS. To rank these ligands according to their binding affinity, competition 
experiments were carried out in solution by incubating AR with mixtures containing 
different concentration ratios of 594 and FID. Relative proportion of each complex was 
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determined from relative peak height of the 12+ charge states assuming that the binding of 
these small ligands does not affect the protein response factor.20–22
In the absence of any ligand, ESI mass spectrum shows the detection of the 1:1 AR–NADP+, 
further on called holo AR [Fig. 2(a)]. Analysis performed in the presence of equimolar 
concentrations of both compounds (10 µM, each) reveals the formation of 1:1 holo AR–FID 
(75%) as well as 1:1 holo AR–594 (25%) [Fig. 2(b)], with the population of AR–FID (75%) 
three times higher than that of AR–594 (25%). Doubling either FID or 594 concentration 
again leads to higher proportions of 1:1 holo AR–FID complex (88% and 60%, respectively) 
confirming that FID displays a higher binding affinity to AR than 594 [Fig. 2(c,d)]; tripling 
the 594 leads to a distribution of 44% for FID and 56% for 594 [Fig. 2(e)]. Assuming that 
the peak height is proportional to the concentration and inversely proportional to the Kd, we 
can calculate that the ratio between the Kd of 594 and of FID is 2.7 ± 0.3.
IC50: In order to check whether the observations obtained for the experiments in solution by 
MS were reliable, IC50 values for both inhibitors against AR were measured. As stated 
before, the IC50 value was determined as the compound concentration that inhibits 
enzymatic activity by 50%. This is the parameter checked in pharmaceutical screens for 
AR.23 Values obtained were 26 ± 2 nM for FID and 124 ± 10 nM for 594. If we assume that 
the IC50 values are proportional to Kd, the ratio between the Kd of 594 and of FID is 4.8. 
Both FID and 594 display uncompetitive inhibition, as most of AR inhibitors (ARIs).24 
Moreover, we have compared them in the same experimental conditions, which means that 
IC50 is at least a relative parameter which allows to compare the binding of both inhibitors. 
Also, for uncompetitive inhibitors, IC50 values approximate Ki when the substrate 
concentration used in the assay is much higher than Km, as seen in the Cheng–Prusoff 
derived equation.25 Thus, the IC50 value in this enzyme assay really does provide a measure 
of binding.
Thus, both MS gas-phase measurements and IC50 solution studies indicate that FID is the 
strongest binder. This is even more the case in the published11,12 isothermal titration 
calorimetry (ITC) studies, for which the ratio between the Kd of 594 and of FID is 10.
X-ray crystallography
The Fobs − Fcalc difference map reveals a density corresponding to the superposition of both 
inhibitors, with evident atomic peaks for every atom (Fig. 3). The refinement results show 
that the crystallographic occupancy values (Table II) increase or decrease according to the 
variation of the soaking concentrations.
For the case of FID = 594, for which the soaking concentrations of inhibitors were equal, the 
occupancy of 594 is ~1.7 times higher than the occupancy of FID.
Effect of experimental conditions used in ligand binding
It is important to pay attention to the fact that the binding affinity is highly dependent on 
buffer conditions used. The buffers used in the different methodologies shown here have 
been chosen in a compromise between keeping the protein full functional and a proper 
adaptation to each methodology. The buffer used for the IC50 analysis is 100 mM sodium 
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phosphate buffer pH 7.0. The protein is fully active in these pH conditions, as described.26 
For native MS, a 10 mM ammonium acetate pH 6.8 buffer was used. MS is a powerful 
method for analyzing the active forms of macromolecular complexes of biomolecules. 
However, such native analyses cannot be performed when solutions contain high 
concentrations of non-volatile salts (like in the IC50 assay). Addition of ammonium acetate 
can improve signal stability and reproducibility for native MS assays, and can significantly 
lower adduction and background signals.27 Anyway, MS conditions might not alter AR 
activity, as shown in the native MS analysis of the holoenzyme, where NADP+ is bound to 
AR. For ITC, in the articles cited, AR was prepared in 10 mM HEPES buffer pH 8.0. 
Phosphate buffers are known to have a very small enthalpy of ionization under these 
conditions, whereas HEPES has a much larger value.28 If the selected buffer has a large 
enthalpy of ionization, the measured enthalpy will reflect both buffer ionization and 
complex formation. This can be quite informative if one wishes to determine whether 
protons are taken up or released on complex formation.29 Finally, crystallization conditions 
used were with 50 mM di-ammonium citrate at pH 5.0 (protein buffer) and 50 mM di-
ammonium citrate at pH 5.0, 20% polyethylene glycol (PEG) 6000 (reservoir), as detailed 
before.8,30 This condition is mandatory for growing crystals. Anyway, both NADP+ and the 
carboxylate group are charged, as it can be observed in the crystallographic structures. In the 
case of carboxylate, equal bond lengths C—O indicated that it is charged.8 This is 
coincident with the described reaction mechanism of AR and uncompetitive inhibition 
displayed by both inhibitors.10,31
Indeed, differences in experimental conditions allow only a qualitative comparison between 
results. Anyway, all the methodologies considered here ensure the full functionality of the 
enzyme and, thus, they are feasible to study ligand binding potency.
Structural explanation of differences between solution and X-ray crystallography studies
As discussed above, MS studies indicate a 2.7 times higher occupancy of FID vs 594, while 
X-ray crystallography indicates a 0.6 times lower occupancy. There is a significant 
difference (4.6 times) in occupancy ratios. Other solution studies indicate also a stronger 
binding of FID vs 594 (4.8 times for IC50 studies, 10 times for ITC). Both soaked ligands 
are highly soluble and can enter to the active site pocket, which is accessible. This is also 
proven because AR has been shown as active in the crystalline form32 and because the 
soaking time assayed is long (6 days), allowing the system to reach equilibrium. Thus, 
kinetic effects are not relevant in these conditions (but they are relevant for short time 
scales), while thermodynamics is guiding the ligand binding.
We searched, therefore, a structural explanation for the favored binding of 594 vs FID in the 
crystal. FID binds only to the active site pocket (or anion binding pocket) (Fig. 4), while 594 
binds both to the active site pocket and also to the specificity pocket (Fig. 4). Loop A, 
containing the residues 122–130 (in yellow in Fig. 4) is in closer contact with 594 than with 
FID. In the case of 594, the specificity pocket (marked by S), which is occupied by the 
inhibitor, is at the base of this loop, as shown in Figure 4. The last ring of 594 has close 
hydrophobic contacts with Leu 300 and Phe 122 [Fig. 4(b)], which is itself in contact with 
Ala 130 (Fig. 5). Therefore, 594 binds the base of the loop, decreasing its flexibility. The 
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effect of the inhibitor binding is seen in the configuration of Loop A. For the structures FID 
> 594 and FID = 594, the configuration is similar to that observed in the published structures 
of single-inhibitor AR–594 (PDB 1US0 and 2I16), while for the structure FID > 594 there 
are two conformations corresponding to the structures with the individual inhibitors (Fig. 6, 
magenta for the single-inhibitor AR–FID complex (1PWM) conformation, and cyan for the 
single-inhibitor AR–594 complex (1US0 and 2I16) conformation). The symmetry-related 
residues are shown in yellow, and the complexes in which they appear are indicated in the 
labels. Note that the contacts are similar, but not identical. In particular, symmetry-related 
residue Glu 29 has two conformations in the single-inhibitor AR–594 complex, both making 
an H-bond with Ser 127, and one conformation in the single-inhibitor AR–FID complex. We 
have studied the effect of the different contacts of the inhibitor with Loop A and the 
different packing contacts by looking at the temperature factors of the Loop A residues for 
the different structures. As shown in Figure 7, B-factors in the single-inhibitor AR–FID 
structure are clearly higher than those in the single-inhibitor AR–594 one, and the B-factors 
in the double-inhibitor structures FID < 594 and FID = 594 are intermediate. Those in the 
structure FID > 594 are not shown, since the loop has two conformations, as shown in 
Figure 6. Thus, Loop A is more flexible in the crystal of AR–FID than in the crystal of AR–
594, most likely due to the contacts of 594 with Phe 122 (Fig. 5), which restrains the 
mobility of Loop A. The stabilization of this loop diminishes the entropy cost involved in 
fixing the conformation of Loop A during crystallization. Therefore, the binding of 594 
favors crystallization, and vice versa: the crystal packing favors the binding of 594 over the 
binding of FID. This can explain the difference between the occupancy ratios in solution and 
in the crystal.
It is interesting to see that the opening of the specificity pocket by 594 implies a large 
conformational change around residues 300–301 (see Fig. 4), and both conformations are 
seen in the electron density maps. This is also true for water molecules, which are different 
for the two conformations of the active site (see Fig. 8). Note that both sets of water 
molecules appear in the crystals of FID > 594, FID = 594, and FID < 594 in the same 
positions that they appear in the structures of complexes of single-inhibitor AR–FID 
complex (1PWM) and single-inhibitor AR–594 solved independently (PDB 1US0 and 2I16).
CONCLUSIONS
Crystallographic studies usually concern a complex of an enzyme with a single ligand, and 
the main assumption is that the observations in the crystal can be extrapolated to predict the 
binding in solution. We have asked the question whether more than one ligand can be tried 
in a crystallographic experiment, and to which extent the crystalline state affects ligand 
binding. This is especially relevant for FBS-X screenings, used to identify novel lead 
compounds by academic institutions and pharmaceutical companies.33
Two different types of competition experiments have been performed, as follows:
1. In the co-crystallization experiments with two inhibitors simultaneously, FID and 
594, only 594 is fixed. Furthermore, the resolution obtained for the X-ray 
diffraction data is higher for single-inhibitor AR–594 crystal (0.66 Å) than for 
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single-inhibitor AR–FID crystal (0.9 Å). A possible explanation for this 
observation is that the binding of the AR–594 complex to the growing crystal is 
energetically more favorable than that of the AR–FID complex. Therefore, during 
the crystal growth the AR–594 complex will replace the AR–FID complex, leading 
to a crystal with only AR–594.
2. In the soaking experiments, the results described above show that competition for 
the same site between different ligands is indeed possible in the crystalline state, 
and that the relative occupancy of the ligands is to a first approximation 
proportional to the soaking concentrations. An important corollary of this 
observation is that when the binding site in the protein crystal remains accessible 
for ligands by soaking, there is always equilibrium between bound and unbound 
states, even with several inhibitors.
The question still remains of the influence of the crystal packing on the binding equilibrium. 
In this work, we have tackled this problem and obtained the following results: the occupancy 
of 594 in the crystal is ~1.7 times higher than binding of FID, while in solution the 
occupancy of FID is ~2.7 times stronger than the occupancy of 594 (shown by MS). These 
observations have been linked to a change in the order of the Loop A (residues 122–130). 
Indeed, the ligand 594 fixes this loop through interactions with Phe 122. As this loop 
intervenes in packing contacts, its ordering favors crystallization. Therefore, the relation 
between the packing and the binding is established for this case, and linked to ligand-
induced changes in the order of protein regions involved in packing contacts. We can 
interpret this as a supplementary “crystal packing” ligand binding energy term, which can 
explain the difference between the occupancy ratios in solution and in the crystal as well as 
the obtention of crystals of AR–594 alone in co-crystallization experiments with both 
inhibitors. Nevertheless, this effect has a weak influence on the overall binding energy, 
which remains dominated by the local interactions of the ligand with the target. In summary, 
the main assumption of extrapolation of results of crystallographic studies to studies in 
solution and eventually to in vivo binding can be biased due to the effect of crystallographic 
contacts. This strongly supports the use of additional techniques (i.e., like MS or SPR) to 
further characterize binding in solution and to validate FBS-X screenings. This later point is 
being nowadays reinforced by several publications in the drug-design field.34,35 Overall, the 
case of AR is an illustrative example of the influence of the crystal environment in 
crystallographic studies of ligand binding to proteins.
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Figure 1. 
(a) Chemical formula of 594; (b) chemical formula of FID.
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Figure 2. 
Competition experiments in solution monitored by native mass spectrometry. Holo AR was 
diluted to 10 µM in 10 mM ammonium acetate pH 6.8 either (a) alone or in the presence of 
(b) 10 µM FID + 10 µM 594, (c) 20 µM FID + 10 µM 594, (d) 10 µM FID + 20 µM 594, and 
(e) 10 µM FID + 30 µM 594. Mass spectra represent the +12 charge states of holo AR and 
holo AR/ligand complexes. Relative intensity of each species is given in brackets.
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Figure 3. 
Difference map for the FID = 594 structure data shows the superposition of the inhibitors 
594 and FID in the active site. The Fobs − Fcalc density map in green is contoured at 3σ. The 
models of the inhibitors 594 and FID are colored in blue and magenta, respectively.
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Figure 4. 
Difference in the binding of the inhibitors 594 and FID in the structure FID>594. Inhibitor 
FID (magenta) binds only to the active site while 594 (violet) binds both to the active site 
and to the specificity pocket (marked S). Residues Phe 122, Leu 130, and Leu 300 in the 
conformation that binds 594 are shown in cyan, and residue Leu 300 in the conformation 
that binds FID is shown in magenta. The cartoon representation of the fold in the 
conformation that binds 594 is shown in green.
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Figure 5. 
Detail of the interaction of 594 with Phe 122 and Leu 300 shows their close contact.
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Figure 6. 
Crystal packing contacts of Loop A (residues 125–127) in the structure FID>594. Two 
conformations are observed for these residues, one corresponding to the single-inhibitor 
complex AR–594 (1US0), shown in cyan, and the other to the single-inhibitor AR–FID 
(1PWM), shown in magenta. The symmetry-related residues Asp 36 and Glu 29 are shown 
in yellow, and labeled with “FID” and “594” according to their appearance in the structures 
of the single-inhibitor complexes AR–594 and AR–FID. Note that conformation B of Glu 
129, making an H-bond with Ser 127, appears only in the single-inhibitor AR–594 complex 
and not in the single-inhibitor AR–FID complex.
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Figure 7. 
Comparison of atomic B values in the loop 122–130 for the structures of single-inhibitor 
AR–FID, single-inhibitor AR–594, FID = 594 and FID < 594. [Color figure can be viewed 
in the online issue, which is available at wileyonlinelibrary.com.]
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Figure 8. 
Water molecules in the active site of FID > 594. The active site contains water molecules 
that were observed both in the single-inhibitor AR–594 complex (2I16) and in single-
inhibitor AR–FID complex (1PWM). Water molecule 2227 is present in model 2I16 and not 
present in model 1PWM. Water molecules 4296, 6128, and 4238 are present in model 
1PWM and not present in model 2I16. 2Fo − Fcalc maps are shown for the models 2I16 
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(colored magenta), 1PWM (colored green), and FID>594 (colored blue). All three maps are 
contoured at 1.4 σ.
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Table I
Data Collection and Refinement Statistics for FID > 594, FID = 594, and FID < 594 Models
FID > 594 (2PEV) FID = 594 (2PF8) FID <594 (2PFH)
Space group P21 P21 P21
a, b, c 49.247, 66.667, 47.226 49.339, 66.815, 47.378 49.147, 66.553, 47.238
α, β, γ 90.00, 92.27, 90.00 90.00, 92.10, 90.00 90.0, 92.3, 90.00
Resolution range (Å) 50–0.90 (0.93–0.90) 50–0.85 (0.88–0.85) 50–0.85 (0.88–0.85)
Data collection
  R-sym 0.042 (0.344) 0.034 (0.285) 0.033 (0.235)
  Completeness 0.96 (0.93) 0.99 (0.98) 0.95 (0.69)
  I/sigma(I) 34.5 (3.6) 33.7 (4.5) 25.9 (5.8)
  Measured reflections 908,565 964,213 938,116
  Unique reflections 216,325 267,837 253,545
  Redundancy 4.2 (4.0) 3.6 (3.3) 3.7 (3.6)
Refinement
  Number of reflections 216,325 267,837 253,545
  Number of refined parameters 36,221 36,921 35,241
  Total number of restraints 53,881 55,761 51,709
  Rfree/Rwork (%) (models with hydrogen atoms) 8.8/10.0 8.5/9.5 8.2/9.5
  R-factor for all the data (%) (models with hydrogen atoms) 8.3 7.9 7.8
  Number of protein atoms 3183 3098 3207
    <B> <B> = 10.29 <B> = 6.90 <B> = 8.07
  Number of ions 1 1 1
    <B> <B> = 6.3 <B> = 5.45 <B> = 3.6
  Number of water molecules 727 702 770
    <B> <B> = 20.91 <B> = 17.71 <B> = 18.11
Number of ligands 4 5 5
  Number of atoms in ligands 105 118 118
    <B> <B> = 7.72 <B> = 5.16 <B> = 6.01
  <RMS> deviations
    Bond length (Å) 0.015 0.015 0.026
    Angle (°) 0.034 0.036 0.055
aValues in parentheses are for the last shell.
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Table II
Occupancy Values Obtained During the Main and Additional Rounds of Refinement of the Models FID > 594, 
FID = 594, and FID < 594
FID > 594 (2PEV) FID = 594 (2PF8) FID < 594 (2PFH)
Occupancy values of
  Alternate A (inhibitor 594 and residues 299–305, 309 and water molecules) 0.43 0.63 0.8
  Alternate B (inhibitor FID and residues 299–305, 309 and water molecules) 0.57 0.37 0.2
Occupancy value of Br atom of 594 refined separately 0.4 0.6 0.76
Occupancy values of the inhibitors refined separately
  Inhibitor 594 0.43 0.63 0.8
  Inhibitor FID 0.57 0.37 0.2
Occupancy values of the loop 299–305 refined separately
  Conformation A 0.43 0.61 0.79
  Conformation B 0.57 0.39 0.21
Occupancy of 309 residue refined separately
>  Conformation A 0.4 0.63 0.78
>  Conformation B 0.6 0.37 0.22
Occupancy of the part of inhibitor 594 refined separately 0.42 0.64 0.79
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